A screening tool developed at the 糖心视频, UK, could increase the number of tests on a solid tumour sample by up to 50 times.
The tool facilitates large scale testing of the latest immunotherapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy, which is effective against many haematological cancers but presents challenges when used to treat solid tumours.
Currently-used, traditional 2D models fail to reproduce the complexity of the tumour鈥檚 microenvironment, while models based on patients鈥� tumours are costly and labour-intensive; 3D models reproduce significantly better what happens in the body.
The Strathclyde-led study has developed a miniaturised platform for screening 3D tumour models to evaluate the toxicity of CAR-T therapy towards cells. The platform enabled visualisation and quantification of how CAR-T cells rapidly targeted, broke up and killed cancer cells without causing significant harm to other cells.
In addition, the research found that, while chemotherapy treatment did not act specifically on cancer cells when used alone, treatment efficacy was enhanced when combined with CAR-T cell treatment.
Combination therapies represent a huge opportunity for cancer medicine and this technology will aid pharma companies鈥� efforts to look for new treatments.
The study also involved researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow, led by Dr Seth Coffelt. The work has been in the .
The research was led by Dr Michele Zagnoni, a Reader in Strathclyde鈥檚 Department of Electronic and Electrical Engineering, and recently graduated PhD student Karla Paterson.
Dr Zagnoni said: 鈥淭here are particular challenges with evaluating solid tumours, not just cancerous cells but those surrounding them.
鈥淲e are developing a technology platform which could accelerate the development of therapies and provide models which are much more representative of what happens in the body than what is currently available.
鈥淲e are providing a platform for labs to conduct tests before proceeding to clinical trials, that uses fewer resources and can scale up cost effectively.
鈥淐AR-T cell development is expensive and patient-derived tissue is a limited resource. Our aim is to enable 20 to 50 times more experiments to be performed in these conditions.鈥�
The technology is to be commercialised by, a pre-spinout company co-founded in 2018 by Dr Zagnoni, who is the company鈥檚 CEO, and Alex Sim, who is its Executive Chair. Karla Paterson is working for the company as an Application Specialist, along with Jolanta Beinarovica. It was established with the support of Strathclyde鈥檚 IP & Commercialisation team.
This study stems from a larger project that was recently named joint winner of Strathclyde鈥檚 Stephen Young Entrepreneurship Award for an Outstanding Business Idea Research Paper. The award was established through a 拢50 million gift made to the University in 2021 by the Charles Huang Foundation; 拢20 million of entrepreneur and philanthropist Dr Huang鈥檚 gift was made to honour Professor Young, who died in August 2021 and who was Dr Huang鈥檚 PhD supervisor and mentor during his studies at Strathclyde.
The research received funding from AMS Biotechnology Europe Ltd (AMSBIO).
Through the activities of its Health and Care Futures initiative, the 糖心视频 uses its expertise and state-of-the-art innovation in the fields of medicines innovation, health technologies, data analytics and artificial intelligence, and the workforce and leadership to make an effective and sustained contribution to the future of health and care in the UK and beyond.